Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 17

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

Tran, Duc, Beeler, J. Scott, Liu, Jie, Wiley, Brian, Chan, Irenaeus C.C., Xin, Zilan, Kramer, Michael H., Batchi-Bouyou, Armel L., Zong, Xiaoyu, Walter, Matthew J., Petrone, Giulia E.M., Chlamydas, Sarantis, Ferraro, Francesca, Oh, Stephen T., Link, Daniel C., Busby, Ben, Cao, Yin, Bolton, Kelly L.·2024·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-23-3468PMC PMC11292192

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Clonal hematopoiesis (CH) is thought to be the origin of myeloid neoplasms (MN). Yet, our understanding of the mechanisms driving CH progression to MN and clinical risk prediction of MN remains limited. The human proteome reflects complex interactions between genetic and epigenetic regulation of biological systems. We hypothesized that the plasma proteome might predict MN risk and inform our understanding of the mechanisms promoting MN development. Experimental Design: We jointly characterized CH and plasma proteomic profiles of 46,237 individuals in the UK Biobank at baseline study entry. During 500,036 person-years of follow-up, 115 individuals developed MN. Cox proportional hazard regression was used to test for an association between plasma protein levels and MN risk. Results: We identified 115 proteins associated with MN risk, of which 30% (N = 34) were also associated with CH. These were enriched for known regulators of the innate and adaptive immune system. Plasma proteomics improved the prediction of MN risk (AUC = 0.85; P = 5×10–9) beyond clinical factors and CH (AUC = 0.80). In an independent group (N = 381,485), we used inherited polygenic risk scores (PRS) for plasma protein levels to validate the relevance of these proteins toMNdevelopment. PRS analyses suggest that most MN-associated proteins we identified are not directly causally linked toMN risk, but rather represent downstream markers of pathways regulating the progression of CH to MN. Conclusions: These data highlight the role of immune cell regulation in the progression of CH to MN and the promise of leveraging multi-omic characterization of CH to improveMN risk stratification. See related commentary by Bhalgat and Taylor, p. 3095

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-23-3468

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Association between plasma protein levels, incident myeloid neoplasm (MN), and clonal hematopoiesis (CH). A, Multivariable Cox regression adjusted for age, sex, smoking status, year of sample collection, blood count measurements, and the top 10 principal components of genetic ancestry was used to test for an association between plasma protein expression and MN (left). Multivariable logistic regression adjusted for the same covariates was used to test for an association with CH (right). The y-axis displays the z-score transformed beta coefficients from the regressions. Each circle represents one protein colored by statistical significance (FDR-corrected P value < 0.05) for MN (blue), CH (green), MN and CH (red), or none (gray). The top 20 results in each plot are labeled by protein name. B, Multivariable Cox for the top 25 proteins associated with MN risk with (teal) or without (red) correction for CH (by maximum VAF) regression for MN risk. Shown are the hazard ratios and their 95% confidence intervals. C, Discrimination of MN risk incorporating basic clinical features alone or alongside CH and/or proteomics. The clinical model incorporates age, sex, ancestry, smoking status, blood counts, and sample age. Receiver operating (ROC) curves include the mean AUC and 95% confidence interval (lighter shading) generated from 100-fold cross-validation.
Figure 1. Association between plasma protein levels, incident myeloid neoplasm (MN), and clonal hematopoiesis (CH). A, Multivariable Cox regression adjusted for age, sex, smoking status, year of sample collection, blood count measurements, and the top 10 principal components of genetic ancestry was used to test for an association between plasma protein expression and MN (left). Multivariable logistic regression adjusted for the same covariates was used to test for an association with CH (right). The y-axis displays the z-score transformed beta coefficients from the regressions. Each circle represents one protein colored by statistical significance (FDR-corrected P value < 0.05) for MN (blue), CH (green), MN and CH (red), or none (gray). The top 20 results in each plot are labeled by protein name. B, Multivariable Cox for the top 25 proteins associated with MN risk with (teal) or without (red) correction for CH (by maximum VAF) regression for MN risk. Shown are the hazard ratios and their 95% confidence intervals. C, Discrimination of MN risk incorporating basic clinical features alone or alongside CH and/or proteomics. The clinical model incorporates age, sex, ancestry, smoking status, blood counts, and sample age. Receiver operating (ROC) curves include the mean AUC and 95% confidence interval (lighter shading) generated from 100-fold cross-validation.CC BY-NC-ND · PubMed Central
Figure 2. Association between polygenic risk score (PRS) for plasma protein levels and MN in an independent subset of the UKBB (A). Association between global (i.e., genome-wide) PRS (PRSglobal-pQTL) for plasma protein levels and risk of MN. For each protein, PRSs for each individual were constructed by summing the product of the beta coefficients for the association between and the number of alternate alleles for each protein quantitative loci detected through a genome-wide interrogation. The beta coefficients were obtained from SNP-protein association analysis. Displayed are the hazard ratio and 95% confidence intervals for proteins in which genetically predicted levels were significantly associated with MN risk. B, Two-sample Mendelian randomization (MR) analyses of the causal impact of plasma protein levels on MN risk. Each dot represents the estimated MR effect for the corresponding protein with the corresponding 95% confidence interval.
Figure 2. Association between polygenic risk score (PRS) for plasma protein levels and MN in an independent subset of the UKBB (A). Association between global (i.e., genome-wide) PRS (PRSglobal-pQTL) for plasma protein levels and risk of MN. For each protein, PRSs for each individual were constructed by summing the product of the beta coefficients for the association between and the number of alternate alleles for each protein quantitative loci detected through a genome-wide interrogation. The beta coefficients were obtained from SNP-protein association analysis. Displayed are the hazard ratio and 95% confidence intervals for proteins in which genetically predicted levels were significantly associated with MN risk. B, Two-sample Mendelian randomization (MR) analyses of the causal impact of plasma protein levels on MN risk. Each dot represents the estimated MR effect for the corresponding protein with the corresponding 95% confidence interval.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 62

  1. Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405 · DOI · Paper page
  2. Jaiswal, 2014, Agerelated clonal hematopoiesis associated with adverse outcomes, N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617 · DOI · Paper page
  3. Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 20, 1472, 10.1038/nm.3733 · DOI · Paper page
  4. McKerrell, 2017, JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics, Blood Advances, 1, 968, 10.1182/bloodadvances.2017007047 · DOI
  5. Desai, 2018, Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat Med, 24, 1015, 10.1038/s41591-018-0081-z · DOI · Paper page
  6. Gu, 2023, Multiparameter prediction of myeloid neoplasia risk, Nat Genet, 55, 1523, 10.1038/s41588-023-01472-1 · DOI · Paper page
  7. Weeks, 2023, Prediction of risk for myeloid malignancy in clonal hematopoiesis, NEJM Evid, 2, 10.1056/evidoa2200310 · DOI · Paper page
  8. Kornblau, 2009, Functional proteomic profiling of AML predicts response and survival, Blood, 113, 154, 10.1182/blood-2007-10-119438 · DOI
  9. Hu, 2019, A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia, Nat Biomed Eng, 3, 889, 10.1038/s41551-019-0387-2 · DOI
  10. Van Dijk, 2020, Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective, Expert Review of Proteomics, 17, 1, 10.1080/14789450.2020.1717951 · DOI
  11. Kramer, 2022, Proteomic and phosphoproteomic landscapes of acute myeloid leukemia, Blood, 140, 1533, 10.1182/blood.2022016033 · DOI
  12. Geffen, 2023, Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation, Cell, 186, 3945, 10.1016/j.cell.2023.07.013 · DOI
  13. Liu, 2021, Large-scale and highresolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting, Nat Commun, 12, 4961, 10.1038/s41467-021-25202-5 · DOI
  14. Chinese Human Proteome Project (CNHPP) Consortium, 2019, Proteomics identifies new therapeutic targets of earlystage hepatocellular carcinoma, Nature, 567, 257, 10.1038/s41586-019-0987-8 · DOI
  15. Meissner, 2022, The emerging role of mass spectrometry-based proteomics in drug discovery, Nat Rev Drug Discov, 21, 637, 10.1038/s41573-022-00409-3 · DOI
  16. Sudlow, 2015, UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age, PLoS Med, 12, e1001779, 10.1371/journal.pmed.1001779 · DOI · Paper page
  17. Van Hout, 2020, Exome sequencing and characterization of 49,960 individuals in the UK Biobank, Nature, 586, 749, 10.1038/s41586-020-2853-0 · DOI · Paper page
  18. Loh, 2018, Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations, Nature, 559, 350, 10.1038/s41586-018-0321-x · DOI · Paper page
  19. Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet, 81, 559, 10.1086/519795 · DOI · Paper page
  20. Brion, 2013, Calculating statistical power in mendelian randomization studies, Int J Epidemiol, 42, 1497, 10.1093/ije/dyt179 · DOI · Paper page
  21. Li, 2017, AMIGO2 modulates T-cell functions and its deficiency in mice ameliorates experimental autoimmune encephalomyelitis, Brain Behav Immun, 62, 110, 10.1016/j.bbi.2017.01.009 · DOI
  22. Park, 2015, AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation, J Cell Biol, 211, 619, 10.1083/jcb.201503113 · DOI
  23. Sierro, 2011, The CD4-like molecule LAG-3, biology and therapeutic applications, Expert Opin Ther Targets, 15, 91, 10.1517/14712598.2011.540563 · DOI
  24. Sintes, 2007, Characterization of mouse CD229 (Ly9), a leukocyte cell surface molecule of the CD150 (SLAM) family, Tissue Antigens, 70, 355, 10.1111/j.1399-0039.2007.00909.x · DOI
  25. Somuncular, 2023, Combination of CD49b and CD229 reveals a subset of multipotent progenitors with short-term activity within the hematopoietic stem cell compartment, Stem Cells Transl Med, 12, 720, 10.1093/stcltm/szad057 · DOI
  26. Kovalovsky, 2021, Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia, Leukemia, 35, 2581, 10.1038/s41375-021-01188-3 · DOI
  27. Patel, 1999, OB-BP1/Siglec-6. A leptinand sialic acid-binding protein of the immunoglobulin superfamily, J Biol Chem, 274, 22729, 10.1074/jbc.274.32.22729 · DOI
  28. Fonseca, 2020, Deficiency in the glycosyltransferase Gcnt1 increases susceptibility to tuberculosis through a mechanism involving neutrophils, Mucosal Immunol, 13, 836, 10.1038/s41385-020-0277-7 · DOI
  29. Perkey, 2020, GCNT1-mediated O-glycosylation of the sialomucin CD43 is a sensitive indicator of notch signaling in activated T cells, J Immunol, 204, 1674, 10.4049/jimmunol.1901194 · DOI
  30. Lyck, 2015, The physiological roles of ICAM-1 and ICAM-2 in neutrophil migration into tissues, Curr Opin Hematol, 22, 53, 10.1097/MOH.0000000000000103 · DOI
  31. Agresta, 2018, The emerging role of CD244 signaling in immune cells of the tumor microenvironment, Front Immunol, 9, 2809, 10.3389/fimmu.2018.02809 · DOI
  32. Kerrigan, 2010, Syk-coupled C-type lectin receptors that mediate cellular activation via single tyrosine based activation motifs, Immunol Rev, 234, 335, 10.1111/j.0105-2896.2009.00882.x · DOI
  33. Pinho, 2022, VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells, Nat Cell Biol, 24, 290, 10.1038/s41556-022-00849-4 · DOI
  34. Gupta, 2017, JAK2-V617F activates b1-integrin–mediated adhesion of granulocytes to vascular cell adhesion molecule 1, Leukemia, 31, 1223, 10.1038/leu.2017.26 · DOI
  35. Köhler, 2020, Red blood cell-derived semaphorin 7A promotes thrombo-inflammation in myocardial ischemia-reperfusion injury through platelet GPIb, Nat Commun, 11, 1315, 10.1038/s41467-020-14958-x · DOI
  36. Morote-Garcia, 2012, Endothelial semaphorin 7A promotes neutrophil migration during hypoxia, Proc Natl Acad Sci USA, 109, 14146, 10.1073/pnas.1202165109 · DOI
  37. Dietrich, 2000, Cutting edge: signalregulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells, J Immunol, 164, 9, 10.4049/jimmunol.164.1.9 · DOI
  38. Groom, 2011, CXCR3 in T-cell function, Exp Cell Res, 317, 620, 10.1016/j.yexcr.2010.12.017 · DOI
  39. Tokunaga, 2018, CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy, Cancer Treat Rev, 63, 40, 10.1016/j.ctrv.2017.11.007 · DOI · Paper page
  40. Averbeck, 2007, Switch in syndecan-1 and syndecan-4 expression controls maturation associated dendritic cell motility, Exp Dermatol, 16, 580, 10.1111/j.1600-0625.2007.00568.x · DOI
  41. Martin, 2019, CD97 is a critical regulator of acute myeloid leukemia stem cell function, J Exp Med, 216, 2362, 10.1084/jem.20190598 · DOI
  42. Nakamura-Ishizu, 2020, Multifaceted roles of thrombopoietin in hematopoietic stem cell regulation, Ann N Y Acad Sci, 1466, 51, 10.1111/nyas.14169 · DOI
  43. Niu, 2021, Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia, Blood, 137, 3641, 10.1182/blood.2020007651 · DOI
  44. Pearson, 2019, AXL inhibition extinguishes primitive JAK2 mutated myeloproliferative neoplasm progenitor cells, Hemasphere, 3, e233, 10.1097/HS9.0000000000000233 · DOI
  45. Tischer, 2019, Platelet-type von willebrand disease: local disorder of the platelet GPIbα β-switch drives high-affinity binding to von Willebrand factor, J Thromb Haemost, 17, 2022, 10.1111/jth.14597 · DOI
  46. Kauskot, 2013, PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway, Blood, 121, 5208, 10.1182/blood-2012-10-462887 · DOI
  47. Nanda, 2005, Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contactinduced activation, J Biol Chem, 280, 24680, 10.1074/jbc.M413411200 · DOI
  48. Volz, 2020, BIN2 orchestrates platelet calcium signaling in thrombosis and thrombo-inflammation, J Clin Invest, 130, 6064, 10.1172/JCI136457 · DOI
  49. Itkin, 2012, FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 downregulation, Blood, 120, 1843, 10.1182/blood-2011-11-394692 · DOI
  50. Talbot, 2018, Regulatory roles of sortilin and SorLA in immune-related processes, Front Pharmacol, 9, 1507, 10.3389/fphar.2018.01507 · DOI
  51. Koschmieder, 2020, Role of inflammation in the biology of myeloproliferative neoplasms, Blood Rev, 42, 100711, 10.1016/j.blre.2020.100711 · DOI
  52. Khaldoyanidi, 2021, Immune biology of acute myeloid leukemia: implications for immunotherapy, J Clin Oncol, 39, 419, 10.1200/JCO.20.00475 · DOI
  53. Abegunde, 2018, An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis, Exp Hematol, 59, 60, 10.1016/j.exphem.2017.11.002 · DOI · Paper page
  54. Pasupuleti, 2023, Obesity-induced inflammation exacerbates clonal hematopoiesis, J Clin Invest, 133, e163968, 10.1172/JCI163968 · DOI
  55. Méndez-Ferrer, 2020, Bone marrow niches in haematological malignancies, Nat Rev Cancer, 20, 285, 10.1038/s41568-020-0245-2 · DOI
  56. Mills, 2023, IL17 and IL17-producing cells in protection versus pathology, Nat Rev Immunol, 23, 38, 10.1038/s41577-022-00746-9 · DOI
  57. de Mooij, 2017, Targeting the interleukin-1 pathway in patients with hematological disorders, Blood, 129, 3155, 10.1182/blood-2016-12-754994 · DOI
  58. Chung, 2009, Critical regulation of early Th17 cell differentiation by interleukin-1 signaling, Immunity, 30, 576, 10.1016/j.immuni.2009.02.007 · DOI
  59. Hoang, 1988, Interleukin 1 enhances growth factor-dependent proliferation of the clonogenic cells in acute myeloblastic leukemia and of normal human primitive hemopoietic precursors, J Exp Med, 168, 463, 10.1084/jem.168.2.463 · DOI
  60. Delvaeye, 2009, Coagulation and innate immune responses: can we view them separately?, Blood, 114, 2367, 10.1182/blood-2009-05-199208 · DOI
  61. Unruh, 2020, Beyond thrombosis: the impact of tissue factor signaling in cancer, J Hematol Oncol, 13, 93, 10.1186/s13045-020-00932-z · DOI
  62. Milsom, 2009, Tissue factor and cancer stem cells: is there a linkage? Arterioscler Thromb, Vasc Biol, 29, 2005, 10.1161/ATVBAHA.108.177444 · DOI

Cited by

Metadata

Authors
Tran, D., Beeler, J. S., Liu, J., Wiley, B., Chan, I. C. C., Xin, Z., Kramer, M. H., Batchi-Bouyou, A. L., Zong, X., Walter, M. J., Petrone, G. E. M., Chlamydas, S., Ferraro, F., Oh, S. T., Link, D. C., Busby, B., Cao, Y., & Bolton, K. L.
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2024-03-06
Volume
30
Issue
15
Pages
3220-3228
ISSN
  • 1078-0432
  • 1557-3265
DOI
10.1158/1078-0432.ccr-23-3468
PMC
PMC11292192
Cited by
17
References
9
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 148 d)
Funders
  • Edward P. Evans Foundation
  • American Society of Hematology
  • National Institutes of Health (K08 CA241318)
  • Children's Discovery Institute
  • V Foundation for Cancer Research
  • Damon Runyon Cancer Research Foundation
  • UK Biobank Resource (55288)
  • UK Biobank Research Analysis Platform

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review